Novartis Excited About Iptacopan But Downcast After Huntington’s Blow
Branaplam Development Halted
The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.
You may also be interested in...
Phase III Success For Roche’s Crovalimab In Crowded PNH Market
Roche is looking to challenge AstraZeneca's dominance in PNH with its subcutaneously administered once-a-month treatment but could struggle to rival the company's and Novartis’s oral therapy.
Bayer's High Hopes For Huntington's Gene Therapy As Novartis’s Branaplam Stumbles
When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.
Wave’s Huntington Drugs Wipe Out As Trials Run Aground
The company now turns to its next-generation Huntington drug, WVE-003.